Updates in Hemodialysis 2015
DOI: 10.5772/59316
|View full text |Cite
|
Sign up to set email alerts
|

Iatrogenic Iron Overload in Dialysis Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(9 citation statements)
references
References 62 publications
0
9
0
Order By: Relevance
“…The poor prognosis of ESRD in the pre-ESA era, together with the severity of dialytic complications (especially full-blown clinical iron overload owing to transfusions and sole use of IV iron products), provided valuable lessons on the use of iron supplements, mainly based on autopsy studies [ 3 ]. Indeed, post-mortem studies of dialysis patients with severe hepatosplenic sideroses in the late 1970s and early 1980s showed abundant iron deposits in the liver, spleen, adrenal glands, lymph nodes, and lungs, with generally smaller amounts in the kidneys, pancreas, and heart [ 46 – 48 ].…”
Section: Lessons Learned From Hemodialysis-associated Hemosiderosis Imentioning
confidence: 99%
See 4 more Smart Citations
“…The poor prognosis of ESRD in the pre-ESA era, together with the severity of dialytic complications (especially full-blown clinical iron overload owing to transfusions and sole use of IV iron products), provided valuable lessons on the use of iron supplements, mainly based on autopsy studies [ 3 ]. Indeed, post-mortem studies of dialysis patients with severe hepatosplenic sideroses in the late 1970s and early 1980s showed abundant iron deposits in the liver, spleen, adrenal glands, lymph nodes, and lungs, with generally smaller amounts in the kidneys, pancreas, and heart [ 46 – 48 ].…”
Section: Lessons Learned From Hemodialysis-associated Hemosiderosis Imentioning
confidence: 99%
“…Routine use of recombinant erythropoeisis-stimulating agents (ESA) over the past three decades has enabled anemia to be partially corrected in most patients with end-stage renal disease (ESRD), thereby improving their quality of life and reducing the need for blood transfusion [ 1 ]. ESA use frequently leads to iron deficiency, owing to massive transfer of stored iron to erythroid progenitor cells [ 2 ], inadequate iron mobilization from repleted storage sites (resulting in functional iron deficiency), and blood loss related to hemodialysis itself, and also to routine blood sampling for laboratory tests and occult fecal bleeding owing to uremic enteropathy [ 1 3 ]. In fact, most ESA-treated hemodialysis patients receive parenteral iron to ensure sufficient available iron before and during ESA therapy [ 3 , 4 ].…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations